Skip to main content

Advertisement

SpringerLink
Log in

Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

The availability of selective inhibitors of the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase (PDE5) has created increasing interest in unlocking the therapeutic potential of PDE5 inhibition in cardiovascular diseases that are marked by dysfunction of nitric oxide (NO)-cGMP signaling. Pulmonary arterial hypertension (PAH) and heart failure (HF) are characterized by pulmonary arterial vasoconstriction that is thought to be caused by relative deficiencies of vasodilators such as NO and exaggerated production of vasoconstrictors such as endothelin. PDE5 is abundant in the pulmonary vasculature where it catabolizes cGMP, the second messenger of NO. Inhibition of PDE5 has been shown to lower pulmonary vascular resistance in PAH and HF by augmenting local cGMP. This review outlines the therapeutic potential of PDE5 inhibition for the treatment of PAH and HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725–748.

    PubMed  CAS  Google Scholar 

  2. Wallis RM, Corbin JD, Francis SH, et al.: Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999, 83:3C-12C. Wallis et al. identified phosphodiesterase isoenzymes by substrate specificity and phosphodiesterase antibodies. This study delineates the tissue distribution of PDE5 and concludes that PDE5 is present in various vascular beds, and in platelets but not in human cardiac ventricles.

    Article  PubMed  CAS  Google Scholar 

  3. Maurice DH, Palmer D, Tilley DG, et al.: Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003, 64:533–546.

    Article  PubMed  CAS  Google Scholar 

  4. Reffelmann T, Kloner RA: Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003, 108:239–244.

    Article  PubMed  Google Scholar 

  5. Butcher RW, Sutherland EW: Adenosine 3’5’-phosphate in biological materials. J Biol Chem 1962, 237:1244–1250.

    PubMed  CAS  Google Scholar 

  6. Gresser U, Gleiter CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 2002, 7:435–446.

    PubMed  CAS  Google Scholar 

  7. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997, 336:111–117.

    Article  PubMed  CAS  Google Scholar 

  8. Lincoln TM, Dey N, Sellak H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001, 91:1421–1430.

    PubMed  CAS  Google Scholar 

  9. Steudel W, Hurford WE, Zapol WM: Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999, 91:1090–1121.

    Article  PubMed  CAS  Google Scholar 

  10. Rabe KF, Tenor H, Dent G, et al.: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.

    PubMed  CAS  Google Scholar 

  11. Thomas MK, Francis SH, Corbin JD: Characterisation of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990, 265:14964–14970.

    PubMed  CAS  Google Scholar 

  12. Sebkhi A, Strange JW, Phillips SC, et al.: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003, 107:3230–3235.

    Article  PubMed  CAS  Google Scholar 

  13. MacLean MR, Johnston ED, McCulloch KM, et al.: Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat. J Pharmacol Exp Ther 1997, 283:619–624.

    PubMed  CAS  Google Scholar 

  14. Hanson KA, Ziegler JW, Rybalkin SD, et al.: Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998, 275:L931-L941.

    PubMed  CAS  Google Scholar 

  15. Zhao L, Mason NW, Morrell NW, et al.: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424–428.

    PubMed  CAS  Google Scholar 

  16. Schermuly RT, Kreisselmeier KP, Ghofrani HY, et al.: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Resp Crit Care Med 2004, 169:39–45.

    Article  PubMed  Google Scholar 

  17. Ichinose F, Erana-Garcia J, Hromi J, et al.: Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001, 29:1000–1005.

    Article  PubMed  CAS  Google Scholar 

  18. Lepore JJ, Maroo A, Pereira NL, et al.: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002, 90:677–680. This study demonstrates that sildenafil improves cardiac performance and augments and prolongs the hemodynamic effects of inhaled NO in patients with PAH.

    Article  PubMed  CAS  Google Scholar 

  19. Michelakis ED, Tymchak W, Noga M, et al.: Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003, 108:2066–2069. This small but carefully done study demonstrates that chronic administration of sildenafil to patients with PAH (n = 5) results in improvement in exercise capacity and PVR, while inducing regression of RV hypertrophy. If these results can be duplicated in large randomized trials of PDE5 inhibitors for the treatment of PAH, it will represent a significant advance in the therapy for this devastating disease.

    Article  PubMed  CAS  Google Scholar 

  20. Sastry BK, Narasimhan C, Reddy NK, et al.: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149–1153.

    Article  PubMed  CAS  Google Scholar 

  21. Ghofrani HA, Wiedemann R, Rose F, et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002, 360:895–900.

    Article  PubMed  CAS  Google Scholar 

  22. Lewis GD, Bloch KD, Semigran MJ: Pulmonary embolism superimposed on congenital VSD: sildenafil to the rescue. Cardiol Rev 2004, 12:188–190.

    Article  PubMed  Google Scholar 

  23. Atz AM, Lefler AK, Fairbrother DL, et al.: Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002, 124:628–629.

    Article  PubMed  Google Scholar 

  24. Mychaskiw G, Sachdev V, Heath BJ: Sildenafil facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001, 13:218–220.

    Article  PubMed  CAS  Google Scholar 

  25. Wilkins H, Guth A, Konig J, et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218–1222.

    Google Scholar 

  26. Di SalvoTG, Mathier M, Semigran MJ, et al.: Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995, 25:1143–1153.

    Article  PubMed  Google Scholar 

  27. Franciosa JA, Baker BJ, Seth L: Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 1985, 110:807–813.

    Article  PubMed  CAS  Google Scholar 

  28. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718–1723.

    PubMed  CAS  Google Scholar 

  29. Kiowski W, Sutsch G, Hunziker P, et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732–736.

    Article  PubMed  CAS  Google Scholar 

  30. Givertz MM, Colucci WS, Lejemtel TH, et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000, 101:2922–2927.

    PubMed  CAS  Google Scholar 

  31. Loh E, Stamler JS, Hare JM, et al.: Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994, 90:2780–2785.

    PubMed  CAS  Google Scholar 

  32. Semigran MJ, Cockrill BA, Kacmarek R, et al.: Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994, 24:982–988.

    Article  PubMed  CAS  Google Scholar 

  33. Koelling TM, Kirmse M, Di Salvo TG, et al.: Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998, 81:1494–1497.

    Article  PubMed  CAS  Google Scholar 

  34. Rabe KF, Tenor H, Dent G, et al.: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.

    PubMed  CAS  Google Scholar 

  35. Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845–851.

    Article  PubMed  CAS  Google Scholar 

  36. Lepore JJ, Maroo A, PereiraNL, et al.:Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.Chest 2004, In press.

  37. Lachman J, Camuso J, Lewis G, et al.: Sildenafil improves hemodynamics and exercise tolerance in patients with advanced heart failure [abstract]. Circulation 2002, 106(Suppl):II-469.

    Google Scholar 

  38. Bocchi EA, Guimaraes G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106:1097–1103.

    Article  PubMed  Google Scholar 

  39. Webster LJ, Michelakis ED, Davis T, Archer SL: Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004, 164:514–520.

    Article  PubMed  CAS  Google Scholar 

  40. Cockrill BA, Kacmarek RM, Fifer MA, et al.: Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001, 119:128–136.

    Article  PubMed  CAS  Google Scholar 

  41. Colucci WS, Jaski BE, Fifer MA, et al.: Milrinone: a positive inotropic vasodilator. Trans Assoc Am Physicians 1984, 97:124–133.

    PubMed  CAS  Google Scholar 

  42. Burstein S, Semigran MJ, Dec GW, et al.: Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. J Am Coll Cardiol 1992, 20:822–829.

    Article  PubMed  CAS  Google Scholar 

  43. Kotera J, Fujishige K, Akatsuka H, et al.: Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998, 273:26982–26990.

    Article  PubMed  CAS  Google Scholar 

  44. Yanaka N, Kotera J, Ohtsuka A, et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998, 255:391–399.

    Article  PubMed  CAS  Google Scholar 

  45. Corbin J, Rannels S, Neal D, et al.: Sildenafil citrate does not effect cardiac contractility in human or dog heart. Curr Med Res Opin 2003, 19:747–752.

    Article  PubMed  CAS  Google Scholar 

  46. Senzaki H, Smith CJ, Juang GJ, et al.: Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001, 15:1718–1726. These authors report evidence of PDE5A activity in canine cardiomyocytes, which remains controversial. PDE5A inhibition was observed to markedly attenuate β-adrenergic responsiveness in normal canine hearts but not in dogs with HF induced by tachypacing. These findings suggest that PDE5 modulates β-adrenergic responsiveness and that reduction of PDE5 activity in the failing heart may contribute to the characteristic reduced β-adrenergic responsiveness that is observed in HF.

    Article  PubMed  CAS  Google Scholar 

  47. Hare JM, Givertz MM, Creager MA, Colucci WS: Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998, 97:161–166.

    PubMed  CAS  Google Scholar 

  48. Hare JM, Lofthouse RA, Juang GJ, et al.: Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Circ Res 2000, 86:1085–1092.

    PubMed  CAS  Google Scholar 

  49. Chen HH, Burnett JC: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999, 111:406–416.

    PubMed  CAS  Google Scholar 

  50. Hare JM, Loh E, Creager MA, Colucci WS: Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995, 92:2198–2203.

    PubMed  CAS  Google Scholar 

  51. Stief CG, Ückert S, Becker AJ, et al.: Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000, 55:146–150.

    Article  PubMed  CAS  Google Scholar 

  52. Mittleman MA, Glasser DB, Orazem J: Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003, 57:597–600.

    PubMed  CAS  Google Scholar 

  53. Morales A, Gingell C, Collins M, et al.: Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998, 10:69–74.

    Article  PubMed  CAS  Google Scholar 

  54. Melvin D, Cheitlin MD, Hutter AM, et al.: ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999, 99:168–177.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Bigelow 800, Massachusetts General Hospital, Fruit Street, 02114, Boston, MA, USA

    Marc J. Semigran MD

Authors
  1. Gregory D. Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc J. Semigran MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewis, G.D., Semigran, M.J. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 1, 183–189 (2004). https://doi.org/10.1007/s11897-004-0007-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-004-0007-6

Keywords

Search

Navigation